676233-07-1

Basic information

• Product Name: 5-(4-fluoro-phenyl)-1-(4-methanesulfonyl-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester
• Synonyms: 5-(4-fluoro-phenyl)-1-(4-methanesulfonyl-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester
• CAS NO: 676233-07-1
• Molecular Weight: 388.419
• Mol File: 676233-07-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-(4-fluoro-phenyl)-1-(4-methanesulfonyl-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-fluoro-phenyl)-1-(4-methanesulfonyl-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester(676233-07-1)
• EPA Substance Registry System: 5-(4-fluoro-phenyl)-1-(4-methanesulfonyl-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester(676233-07-1)

Safety Data

• Hazardous Substances Data: 676233-07-1(Hazardous Substances Data)

Upstream product

• 1999-00-4 ethyl 3-(4'-fluorophenyl)-3-oxopropionate 
• 76348-92-0 ethyl 1-(4'-fluorophenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate 
• 17852-67-4 4-(methylsulfonyl)phenylhydrazine hydrochloride 

Downstream Products

• 676233-24-2 5-(4-fluoro-phenyl)-1-(4-methanesulfonyl-phenyl)-1H-pyrazole-4-carboxylic acid 

Relevant articles and documents

4-Substituted 1,5-diarylpyrazole, analogues of celecoxib: Synthesis and preliminary evaluation of biological properties

A number of 5-aryl-1-[4-(methylsulfonyl)-phenyl]-1H-pyrazoles and 4-(5-aryl-1H-pyrazol-1-yl)benzenesulfonamides 3, 4, 5, 6, analogues of the COX-2 selective inhibitor celecoxib (celebrex), were synthesized. In order to verify the effects on the biological properties of certain substituents put on position 4 of the pyrazole nucleus, some of these compounds were screened in vivo for their anti-inflammatory and analgesic activities. Moreover, sodium salts of carboxylic acids 4 were tested in vitro for their platelet anti-aggregating properties. The results of these preliminary biological assays showed that new derivatives are not endowed with improved anti-inflammatory and analgesic properties, in comparison with celecoxib. In addition, docking studies were carried out on the most significative compounds to evaluate their interaction mode at the active site of both COX-1 and COX-2. Some remarks about the SAR of this class of COX-inhibitors are drown out.